Movano INC 8-K filings

Corvex, Inc. announced its second quarter 2026 financial results, reporting $3.8 million in revenue and a net loss of $12.8 million, while highlighting a significant increase in contracted annualized recurring revenue for its AI computing platform.

Corvex, Inc. announced the appointment of Seth Demsey as co-CEO, alongside Jay Crystal, effective July 1, 2026, following stockholder approval of new equity and employee stock purchase plans.

Corvex, Inc. has adjourned its 2026 Annual Meeting of Stockholders to July 1, 2026, citing administrative reasons despite strong preliminary support for proposals.

Corvex, Inc. announces the appointment of Chance Moreland, formerly of Morgan Stanley, as its new Chief Financial Officer, effective June 29, 2026, to bolster capital formation and AI infrastructure expansion.

Corvex, Inc. announced its first quarter 2026 financial results, highlighting the completion of its acquisition and transition to an AI cloud computing business.

Corvex, Inc. has filed pro forma financial statements reflecting its March 19, 2026 merger with Corvex Legacy Holdings, Inc., showing combined results for Q1 2026 and FY 2025.

Corvex, Inc. has dismissed RBSM LLP and engaged BDO USA, P.C. as its independent registered public accounting firm following its recent merger.

Corvex Inc. has received notification from Nasdaq that it is now in compliance with the Minimum Stockholders Equity Rule, concluding a period of scrutiny.

Movano Inc. has completed its all-stock merger with Corvex, Inc., will be renamed Corvex, Inc., and has regained Nasdaq compliance, supported by a $40.2 million capital raise.

Movano Inc. filed an 8-K detailing its 2024 financial results, including initial revenue from the Evie Ring, and the impact of recent reverse stock splits.

Movano Inc. stockholders approved a significant increase in authorized common stock and an amendment to its incentive plan at a special meeting on December 16, 2025.

Movano Inc. will combine with AI cloud computing firm Corvex, Inc. in an all-stock merger, creating a pure-play platform for secure AI infrastructure and high-performance inference.

Movano Inc. amended its loan agreement with Evie Holdings LLC, pushing the maturity date to November 5, 2025, a mere two-day extension.

Movano Inc. has filed an amendment to its Certificate of Incorporation to effect a 1-for-10 reverse stock split of its common stock, effective October 10, 2025.

Movano Health announced a 1-for-10 reverse stock split to increase its common stock bid price and maintain Nasdaq listing compliance.

Movano Inc. received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement, adding to existing compliance challenges.

Movano Inc. stockholders approved a reverse stock split authorization, an increase in authorized shares, and elected two directors at the 2025 Annual Meeting.

Movano Health has been granted an extension by Nasdaq to regain compliance with listing rules, including timely financial reporting and minimum bid price requirements.

Movano Health received a Nasdaq notice for failing to timely file its quarterly report and is awaiting a panel decision on its compliance plan to avoid delisting.

Movano Inc. announced the engagement of RBSM LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025.

Movano Inc. has secured $1.5 million in bridge financing at a 12% interest rate, collateralized by all assets, to continue its pursuit of strategic alternatives.

Movano Health received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement and for the late filing of its Form 10-Q, prompting the company to plan an appeal.

Movano Inc.'s independent auditor, Moss Adams LLP, has resigned effective June 24, 2025, as the company explores strategic alternatives, with past audit reports noting a going concern uncertainty and material weaknesses in internal controls.

Movano Inc. (Movano Health) has received a notice from Nasdaq indicating non-compliance due to the delayed filing of its Form 10-Q for the quarter ended March 31, 2025, potentially leading to delisting.

Movano Inc. announces exploration of strategic alternatives, including a potential sale or merger, while also facing resource constraints leading to a delay in filing its quarterly report.

Movano Inc. has appointed Shaheen Wirk as a Class III director and member of the Audit Committee, effective January 2, 2025.

Movano Health announced its Q3 2024 financial results, highlighting the successful re-launch of the Evie Ring and progress on the EvieMED 510(k) application.

Movano Health will implement a 1-for-15 reverse stock split effective October 29, 2024, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement.

Movano Health announced its Q2 2024 financial results, highlighted by preparations for the Evie Ring relaunch and advancements in the EvieMED medical device.

Movano Inc. stockholders approved an increase in authorized shares, an amendment to the 2019 Omnibus Incentive Plan, and a potential reverse stock split at the 2024 Annual Meeting.